SARS-CoV-2 monoclonal antibody combination therapy in patients with COVID-19 and primary antibody deficiency

Link to article at PubMed

J Infect Dis. 2021 Nov 8:jiab554. doi: 10.1093/infdis/jiab554. Online ahead of print.

ABSTRACT

Previous reports highlighted the efficacy of SARS-CoV-2 specific monoclonal antibodies (mAbs) against COVID-19. Here we conducted a prospective study on clinical outcome and antiviral effect of mAbs added to standard of care therapy in SARS-CoV-2 infected patients with Primary Antibody Defects. Median time of SARS-CoV-2 qPCR positivity was shorter in eight patients treated with mAbs (22 days) than in ten patients treated with standard of care therapy only (37 days, p=0.026). Median time of SARS-CoV-2 qPCR positivity from mAbs administration was 10 days. SARS-CoV-2 mAbs treatment was effective and well-tolerated in patients with Primary Antibody Defects.

PMID:34746954 | DOI:10.1093/infdis/jiab554

Leave a Reply

Your email address will not be published. Required fields are marked *